

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50304/091001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/542,238	Applicant Kathleen FRESON et al.
(37 C.F.R. § 1.98(b))		Filing Date July 15, 2005	Group 1644
		IDS Filed	June 17, 2009

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	2002/0182729	December 5, 2002	DiCicco-Bloom et al.
	5,486,472	January 23, 1996	Suzuki et al.
	6,242,563	June 5, 2001	Dong

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	WO 00/05260	February 3, 2000	WIPO	
	WO 00/23096	April 27, 2000	WIPO	
	WO 01/23420	April 5, 2001	WIPO	
	WO 2004/062684	July 29, 2004	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Ashur-Fabian et al., "Identification of VIP/PACAP Receptors on Rat Astrocytes Using Antisense Oligodeoxynucleotides," <i>J. Mol. Neurosci.</i> 9(3):211-222 (1997).
	Bibel and Barde, "Neurotrophins: Key Regulators of Cell Fate and Cell Shape in the Vertebrate Nervous System," <i>Genes Dev</i> 14(23):2919-2937 (2000).
	Busto et al., "Evidence for Multiple Rat VPAC ₁ Receptor States with Different Affinities for Agonists," <i>Cell Signal.</i> 11(9):691-696 (1999).
	Cox et al., "VIP Elevates Platelet Cyclic AMP (cAMP) Levels and Inhibits <i>In Vitro</i> Platelet Activation Induced by Platelet-Activating Factor (PAF)," <i>Peptides</i> 5(2):325-328 (1984).
	Dhanjal et al., "A Novel Role for PECAM-1 in Megakaryocytokinesis and Recovery of Platelet Counts in Thrombocytopenic Mice," <i>Blood</i> 109(10):4237-4244 (2007).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50304/091001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/542,238
		Applicant Kathleen FRESON et al.
		Filing Date July 15, 2005
		Group 1644
(37 C.F.R. § 1.98(b))		IDS Filed June 17, 2009

	Freson et al., "VPAC1 Receptor-Mediated Regulation of Megakaryopoiesis," <i>Blood</i> (ASH Annual Meeting Abstracts) 104:Abstract 735 (2004).
	Freson et al., "The Pituitary Adenylate Cyclase-Activating Polypeptide Is a Physiological Inhibitor of Platelet Activation," <i>J. Clin. Invest.</i> 113(6):905-912 (2004).
	Freson et al., "PACAP and Its Receptor VPAC1 Regulate Megakaryocyte Maturation: Therapeutic Implications," <i>Blood</i> 111(4):1885-1893 (2008).
	Goetzel et al., "Specific Recognition of the Human Neuroendocrine Receptor for Vasoactive Intestinal Peptide by Anti-Peptide Antibodies," <i>Mol. Cell. Neurosci.</i> 5(2):145-152 (1994).
	Kobayashi et al., "Interleukin 11," <i>Leuk. Lymphoma</i> 15(1-2):45-49 (1994).
	Sherwood et al., "The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily," <i>Endocrine Reviews</i> 21(6):619-670 (2000).
	Shima et al., "Characterization of VIP- and Helodermin-Preferring Receptors on Rat Platelets," <i>Regulatory Peptides</i> 63(2-3):99-103 (1996).
	Takizawa et al., "Growth and Maturation of Megakaryocytes Is Regulated by Lnk/Sh2b3 Adaptor Protein Through Crosstalk Between Cytokine- and Integrin-Mediated Signals," <i>Exp. Hematol.</i> 36(7):897-906 (2008).
	Tams et al., "Creation of a Selective Antagonist and Agonist of the Rat VPAC ₁ Receptor Using a Combinatorial Approach with Vasoactive Intestinal Peptide 6-23 as Template," <i>Mol. Pharmacol.</i> 58(5):1035-1041 (2000).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	